SmartMed Technologies appoints Ji-sung Choi to serve as Chairman of International Advisors

SmartMed Technologies today announced that Ji-sung Choi will serve as chairman of SmartMed Technologies' International Advisors.

Online PR News – 22-November-2019 – Yeongdeungpo-gu – In this role, Ji-sung Choi will advise the firm on global strategic issues and oversee the work of our other International Advisors. He will be based in Seoul but frequently travel around Korea.

SmartMed Technologies' Chief Executive Officer, Mr. Hyung-min Joon commented on the appointment saying "Ji-sung has extraordinary knowledge of the global economy and has devoted himself to the tech sector helping emerging economies realize more of their potential. His experience and judgment will be important to our clients and to our focus on helping them identify growth opportunities around the world."

SmartMed Technologies' newly appointed Chairman of International Advisors commented on his appointment saying "SmartMed Technologies is a premier establishment with real promise in medical research."

Prior to his appointment at SmartMed Technologies, Ji-sung Choi was Head of Commodities and Infrastructure for Korea Development Bank. During his tenure, he recapitalized the Bank and expanded financing for developing countries to more than $100 million during the food, fuel and financial crises. He led special initiatives for states coming out of conflict, infrastructure and conservation and the environment.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.